Gout flare in the hand of an elderly person Researchers evaluated the efficacy and safety of anakinra for the treatment of acute gout flares. Undergoing 5 days of therapy with the IL-1 receptor ...

The MarketWatch News Department was not involved in the creation of this content. -- Results of a Phase 2a dose escalating study of lingdolinurad (ABP-671) for chronic gout, which enrolled patients ...

Man on bed with pillow embrace foot with painful swollen gout inflammation Researchers compared the time to complete resolution of acute gout flare between early and late allopurinol initiation. Among ...

ankle gout Researchers studied the association between hospitalization and major cardiovascular events among patients with acute gout. Risk for MACEs was higher in the first 30 days after incident ...

Trial to be conducted by Dr. Hyon Choi at Massachusetts General Hospital and will compare the safety and efficacy of two dose levels of Purified Cortrophin Gel for the treatment of acute gout flares ...

October 2, 2012 — New gout guidelines from the American College of Rheumatology are meant to improve gout management by providing clinicians with clear, readily implemented guidance on urate-lowering ...

Treating the acute flare: Acute gout is very painful. Patients with the condition cannot bear weight on an affected joint. Pain management must be the clinician’s first focus. A number of therapies ...

Patients with gout flares are at heightened risk of acute MI or stroke—above and beyond their already increased cardiovascular risk—over the following 4 to 6 months, an observational study suggests.

Management of a patient allergic to allopurinol can be considered a therapeutic challenge. This article highlights the diversity of medications that can be used to manage hyperuricemia during this ...

Please provide your email address to receive an email when new articles are posted on . Patients with gout were more likely than other patients to receive chronic opioids. Female sex, underweight BMI, ...

Results of a Phase 2a dose escalating study of lingdolinurad (ABP-671) for chronic gout, which enrolled patients with mild to moderate renal impairment, showed the URAT1 inhibitor lowered serum uric ...